Gene Therapy AAV Patents

AAV gene therapy patents cover capsid-serotype and capsid-engineering innovations; transgene-cassette and regulatory-element innovations; manufacturing and purification innovations; and the resulting product (capsid + transgene composition) — with IP held by approved-product developers, capsid-platform licensors, and academic foundational patent holders. MAJOR AAV GENE-THERAPY PATENT HOLDERS: SPARK THERAPEUTICS / ROCHE: Luxturna (voretigene neparvovec), AAV2 delivering RPE65 for inherited retinal dystrophy — the first FDA-approved in vivo gene therapy. NOVARTIS / AVEXIS: Zolgensma (onasemnogene abeparvovec), AAV9 delivering SMN1 for spinal muscular atrophy — systemic CNS-crossing delivery. UNIQURE: Hemgenix (etranacogene), AAV5 delivering Factor IX-Padua for hemophilia B; pioneered the first Western gene therapy (Glybera). BIOMARIN: Roctavian (valoctocogene), AAV5 delivering Factor VIII for hemophilia A. SAREPTA: Elevidys (delandistrogene), AAVrh74 delivering micro-dystrophin for Duchenne muscular dystrophy. REGENXBIO: the NAV Technology Platform (AAV7/8/9/rh10) — licenses novel serotypes widely (Zolgensma's AAV9 traces to this lineage), a major licensing-revenue model. OTHERS: Voyager Therapeutics (TRACER capsid discovery), Ultragenyx, Solid Biosciences, Dyno Therapeutics (AI capsid design), and the University of Pennsylvania / Wilson lab foundational AAV patents that underlie much of the field.

Natural-serotype innovations; engineered/evolved-capsid innovations; tropism-retargeting innovations; and immune-evasion innovations represent core AAV gene-therapy patent domains — and a novel capsid is composition-of-matter, the most defensible AAV asset. SEROTYPE PATENTS: natural AAV serotypes and their capsid sequences (AAV1–AAV9, AAVrh10, AAVrh74) — each gives a different tissue tropism (AAV9/rh10 cross the blood-brain barrier; AAV8 targets liver; AAV5 liver/hemophilia; AAV2 retina), and the isolated capsid sequences are themselves patented (Penn/Wilson, NIH, REGENXBIO). CAPSID-ENGINEERING PATENTS: directed evolution (capsid shuffling, error-prone PCR, in vivo selection — Voyager TRACER, Dyno AI-guided), rational/structure-guided design, peptide-display insertion for retargeting, and ancestral-reconstruction capsids; these create NOVEL capsids claimed as new compositions of matter. TROPISM / RETARGETING PATENTS: capsids engineered for muscle, CNS, photoreceptor, or specific cell types; de-targeting the liver; enhanced transduction efficiency. IMMUNE-EVASION PATENTS: capsids engineered to evade pre-existing neutralizing antibodies (a major clinical barrier — many patients are seropositive), reduced immunogenicity, and shielded capsids. A proprietary engineered capsid with measured tropism and reduced immunogenicity is the highest-value AAV IP because it both enables the product and provides composition-of-matter exclusivity.

Transgene and regulatory-element innovations; vector-genome design innovations; production-system innovations; and purification/analytics innovations represent additional AAV gene-therapy patent domains. TRANSGENE-CASSETTE PATENTS: the therapeutic transgene (often codon-optimized — e.g. FIX-Padua hyperactive variant, micro/mini-dystrophin truncations to fit AAV's ~4.7 kb limit), promoter/enhancer selection (ubiquitous CAG/CBA vs. tissue-specific), inverted terminal repeats ITRs, polyadenylation and intron elements, and self-complementary scAAV designs for faster expression. VECTOR-DESIGN PATENTS: oversized-genome strategies, dual-AAV split-vector systems for large genes, and regulatable expression. MANUFACTURING PATENTS: production platforms — HEK293 triple-transfection (plasmid: vector, rep/cap, helper), Sf9/baculovirus insect-cell system, and stable producer cell lines; suspension bioreactor scale-up and serum-free media; yield and full-capsid-ratio improvement. PURIFICATION / ANALYTICS PATENTS: full/empty capsid separation (CsCl or iodixanol gradient, ion-exchange/AEX chromatography, analytical ultracentrifugation AUC), affinity capture (AAVX resin), and characterization assays (ddPCR titer, capsid identity, potency). Manufacturing and full/empty separation are gating because empty capsids increase immunogenicity and dose, so process IP directly affects safety and cost of goods.

AAV gene therapy startup IP strategy must navigate University of Pennsylvania/Wilson foundational AAV patents (broadly licensed), REGENXBIO NAV serotype patents (AAV8/9/rh10 — frequently a required license), approved-product capsid and transgene estates (Spark, Novartis, BioMarin, uniQure, Sarepta), and a landscape where natural serotypes are heavily patented while novel engineered capsids are the open whitespace; understand that using a natural serotype (AAV8, AAV9) very likely requires a license, that the durable defensible asset is a NOVEL engineered capsid (composition-of-matter) plus a specific transgene cassette, and that manufacturing/full-empty-separation process IP materially affects cost and safety; identify whitespace in immune-evading and tissue-targeted engineered capsids, dual/oversized-vector designs for large genes, and scalable high-full-ratio manufacturing. AAV GENE-THERAPY STARTUP IP STRATEGY: NATURAL SEROTYPES ARE LICENSED, NOVEL CAPSIDS ARE THE IP: AAV8/9/rh10 and the Penn foundational patents likely require a license (REGENXBIO NAV) — the durable, defensible asset is a NOVEL engineered/evolved capsid claimed as composition-of-matter with measured tropism and immune evasion; ENGINEERED CAPSIDS FOR TROPISM + IMMUNE EVASION ARE HIGHEST-VALUE: a capsid that retargets to muscle/CNS, de-targets liver, and evades pre-existing neutralizing antibodies is both the clinical differentiator and the strongest patent; TRANSGENE CASSETTE AND DUAL-VECTOR DESIGNS ARE PATENTABLE: codon-optimized/truncated transgenes (micro-dystrophin, FIX-Padua) and split-AAV for >4.7 kb genes are active terrain; MANUFACTURING IS A COST/SAFETY MOAT: high full-capsid-ratio production and full/empty separation reduce dose, immunogenicity, and COGS — patent the process; WHEN TO PATENT: NOVEL CAPSID/CASSETTE WITH MEASURED TRANSDUCTION: file capsid composition-of-matter once a novel capsid shows measured tropism (transduction efficiency + biodistribution + seroprevalence escape) and the transgene cassette shows expression/efficacy — measured transduction efficiency, tissue specificity, neutralizing-antibody evasion, and full-capsid ratio are the critical AAV IP metrics; KEY FTO CHECKLIST: Penn/Wilson foundational AAV; REGENXBIO NAV AAV7/8/9/rh10 license; AAV9 CNS-crossing (Zolgensma); AAV5 hemophilia (uniQure/BioMarin); AAVrh74 muscle (Sarepta); AAV2 retina (Spark); directed-evolution/AI capsid (Voyager TRACER, Dyno); peptide-display retargeting; FIX-Padua micro-dystrophin codon-optimized cassette; scAAV self-complementary; HEK293 triple-transfection vs Sf9/baculovirus; AAVX affinity AEX full/empty AUC.